Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
Expert Reviews in Molecular Medicine|September 13, 2018
Animal-type melanoma: dog or wolf? A review of the literature and a case reportLuigia Stefania Stucci, Raffaele Palmirotta, Domenica Lovero, et al.
Cardiovascular Drugs and Therapy|June 15, 2020
The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological InsightPietro Scicchitano, Marco Tucci, Maria Consiglia Bellino, et al.
International Journal of Molecular Sciences|August 6, 2020
Non-Melanoma Skin Cancers: Biological and Clinical FeaturesMauro Cives, Francesco Mannavola, Lucia Lospalluti, et al.
Cancers|December 11, 2022
The Analysis of Trends in Survival for Patients with Melanoma Brain Metastases with Introduction of Novel Therapeutic Options before the Era of Combined Immunotherapy-Multicenter Italian-Polish ReportJoanna Placzke, Paweł Teterycz, Pietro Quaglino, et al.
Biomarker Research|April 23, 2024
Immune escape of multiple myeloma cells results from low miR29b and the ensuing epigenetic silencing of proteasome genesPatrizia Leone, Eleonora Malerba, Marcella Prete, et al.
Cancers|December 17, 2024
Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim AnalysisFrancesca Consoli, Marco Tucci, Jacopo Pigozzo, et al.
Cancer Treatment Reviews|June 5, 2018
Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitorsLuigia Stefania Stucci, Stella D'Oronzo, Marco Tucci, et al.
Cancer Management and Research|November 29, 2023
Characteristics of Real-World Patients with High-Risk <i>BRAF</i><sup>V600E/K</sup>-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access ProgramPietro Quaglino, Paolo A Ascierto, Francesca Consoli, et al.
Clinical Sarcoma Research|April 19, 2013
Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment optionsBruno Vincenzi, Anna Maria Frezza, Gaia Schiavon, et al.
Leukemia & Lymphoma|April 4, 2017
Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patientsGiovanni D'Arena, Vittorio Simeon, Luca Laurenti, et al.
Pageof 11